GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » Tax Expense

MediciNova (MediciNova) Tax Expense : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is MediciNova Tax Expense?

MediciNova's tax expense for the months ended in Dec. 2023 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.


MediciNova Tax Expense Historical Data

The historical data trend for MediciNova's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova Tax Expense Chart

MediciNova Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - - - -

MediciNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MediciNova Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediciNova  (NAS:MNOV) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


MediciNova Tax Expense Related Terms

Thank you for viewing the detailed overview of MediciNova's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


MediciNova (MediciNova) Business Description

Traded in Other Exchanges
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Executives
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao director 4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a. officer: Chief Scientific Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr. officer: Chief Financial Officer 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda officer: Chief Medical Officer C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki director C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien officer: Vice President 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037

MediciNova (MediciNova) Headlines

From GuruFocus